Potential advantages of direct-acting thrombin inhibitors

Coronary Artery Disease

Volumn 7, Issue 7, 1996, Pages 497-507

  Philippides, George J ^a   Loscalzo, Joseph ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

heparin; hirudin; thrombin

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN III; ARGATROBAN; HEPARIN; HIRUDIN; HIRULOG; PLACEBO; STREPTOKINASE; THROMBIN; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REBOUND; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0029998044     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199607000-00003     Document Type: Review

References (100)

1. Davies MJ, Thomas AC: Plaque fissuring - the cause of acute myocardial infarction, sudden ischemic death and crescendo angina. Br Heart J 1985, 53:363-373.
2. Falk E: Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983, 50:127-134.
3. Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH: Atherosclerotic plaque rupture and thrombosis: evolving concepts. Circulation 1990, 82 (suppl II):II47-II59.
4. Scharfstein J, Loscalzo J: Molecular approach to antithrombotic therapy. Hosp Pract May 15, 1992, 27:77-86.
5. Harker LA, Mann KG: Thrombosis and fibrinolysis. In Thrombosis in Cardiovascular Disorders. Edited by Fuster V, Verestraete M. Philadelphia: WB Saunders Co; 1992:1-16.
6. Magnusson S: Thrombin and prothrombin. Enzyme 1971, 3:277-321.
7. Stubbs MT, Bode W: A player of many parts: the spothlight falls on thrombins structure. Thromb Res 1993, 69:1-58.
8. Hirsch J: Heparin, New Engl J Med 1991, 324:1565-1574.
9. Loscalzo J, Melnick B, Handin R: The interaction of platelet factor 4 and glycosaminoglycin. Arcg Biochem Biophys 1985, 240:446-455.
10. Weitz JI, Huboda M, Massel D, Maraganore J, Hirsch J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is suspectible to inactivation by antithrombin III independent inhibitors. J Clin Invest 1990, 86:385-391.
11. Johnson PH: Hirudin: clinical potential of a thrombin inhibitor. Ann Rev Med 1994, 45:165-177.
12. Stone SR, Marganore JM: Hirudin interactions with thrombin. In Thrombin: Structure and Function. Edited by Berliner LI. New York: Plenum Press, 1992:219-256.
13. Maraganore JM, Boundon P, Jablonski J, Ramachandran KL: Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of throbin. Biochemistry 1990, 29:7095-7101.
14. Powers JC, Kam CM: Synthetic substrates and inhibitors of thrombin. In Thrombin: Structure and Function. Edited by Berliner LJ. New York: Plenum Press, 1992:117-118.
15. Doutremepuich C, Deharo E, Guyot M, Lalanne MC, Walenga J, Fareed J: Antithrombin activity of recombinant hirudin in the rat: a comparative study with heparin. Thromb Res 1989, 54:435-445
16. Jang I-K, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D: Prevention of pletelet-rich arterial thrombosis by selective thrombin inhibitation. Circulation 1990, 81:219-225.
17. Angelli G, Cosmi B, Nenci CG: The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Thromb Haemostasis 1990, 63:204-207.
18. Haskel EJ, Prager NA, Sobel BE, Abenschein DR: Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991, 83:1048-1056.
19. Rudd MA, George D, Jonstone MT, Moore RT, Collins L, Rabbani LE, et al.: Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic theraphy. Circ Res 1992, 70:829-834
20. Rigel DF, Olson RW, Lappe RW: Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis. Circ Res 1993, 72:1091-1102.
21. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ, et al.: Hirupin, heparin and placebo during deep arterial injury in the pig: the in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990, 82:1476-1484.
22. Garratt KN, Heras M, Holmes DR, Roubin GS, Cheseboro JH: Platelet deposition and thrombosis in arterial stents: effect of hirudin compared with heparin plus antiplatelet therapy [Abstract]. J Am Coll Cardiol 1990, 15 (suppl II):209A.
23. Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC: Effectiveness of recombinant desulphatohirudin In reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991, 84:232-243.
24. Theroux P, Ouiment H, McCans J, Latour JG, Joly P, Levy G, et al.: Aspirin, heparin or both to treat acute unstable angina. N Engi J Med 1988, 319:1105-1111.
25. Lewis HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE 3rd, et al.: Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983, 309:396-403.
26. Cairs JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, et al: Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 1985, 313:1369-1375.
27. Telford AM, Wilson C: Trial of heparin versus atenolol in preventation of myocardial infarction in intermediate coronary syndrome. Lancet 1981, i:1225-1228.
28. Theroux P, Waters D, Lam J, McCans J: Reactivation of unstable • angina after the discontinuation of heparin. N Engl J Med 1992, 327:141-145. This article described the outcome of 403 patients who completed 6 days of blinded therapy without recurrent ischemia in a double-blind, randomized, placebo-controlled trial comparing intravenous heparin, aspirin, both treatments and neither during the acute phase of unstable angina. Early reactivation occurred in 14 out of 107 patients who received heparin only. Concomitant aspirin therapy appeared to prevent this withdrawal phenomenon.
29. Theroux P, Waters D, Qiu S, McCans J, deGuise P, Juneau M, et al.: Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993, 88:2045-2048.
30. Wallentin L for the RISC study group of unstable coronary artery disease: Risk for myocardial infarction and death in a randomized placebocontrolled study [Abstract]. Circulation 1989, 80 (suppl II):419
31. Sharma GVK, Lapsley DE, Vita JA, Sharma S, Coccio E, Adelman B, et al.: Usefulness and tolerability of hirulog, a direct thrombin inhibition, in unstable angina pectoris. Am J Cardiol 1993, 72:1357-1360. This open-label pilot study of 20 patients with unstable angina demonstrated that a 5-day infusion of hirulog was well tolerated and may be effective in prolonging the aPTT and preventing adverse cardiovascular sequelae.
32. Lindon RM, Theroux P, Juneau M, Adelman B, Maraganore J: Initial experience with a direct antithrombin, hirulog, in unstable angina: anticoagulant antithrombotic and clinical effects. Circulation 1993, 88 (part 1):1495-1501. This study demonstrated that hirulog infusions yielded dose-dependent anticoagulant and antithrombotic effects with a favorable clinical success rate in 55 patients presenting with unstable angina.
33. Fuchs J, Cannon CP for the TIMI 7 Investigators: Hirulog in the treatment of unstable angina: results of the TIMI 7 trial. Circulation 1995, 92:727-733. This randomized, double-blind, dose-ranging study of hirulog therapy in 410 patients with unstable angina demonstrated that higher doses of hirulog are well tolerated and show substantial benefit when added to aspirin therapy.
34. Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ et al.: Recombinant hirudin for unstable angina pectoris: a multicenter randomized angiographic trial. Circulation 1994, 89:1557-1566. This trial randomized 163 patients with unstable angina to treatment with escalating doses of hirudin versus intravenous heparin. Hirudin therapy demonstrated better angiographic patency of the culprit arterial lesion compared with herapin infusion.
35. Gold HK, Torres FW, Garabedian HD, Werner W, Jang IK, Khan A, et al.: Evidence for a rebound coagulation phenomenon after cessation of a 4 hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993, 21:1039-1047. This phase I clinical trial evaluated the antithrombotic and clinical effects of argatroban therapy in unstable angina. Argatroban inhibited clotting and thrombin activity but not thrombin formation. Myocardial ischemia did not occur during therapy, but 9 out of 43 patients experienced recurrent angina after infusion cessation.
36. ISAM Study Group: A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM). N Engl J Med 1986, 314:1465-1471.
37. National Heart Foundation of Australia Coronary Thrombolysis Group: Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of muocardial infarction. Lancet 1988, ii:203-207.
38. ISIS-2 (Second International Study of Interact Survival) Collaborative group: Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17 187 cases of suspected acute myocardial infaction: ISIS-2. Lancet 1988, ii:349-360.
39. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR, et al.: Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of early Thrombolysis (ASSET). Lancet 1988, ii:525-530.
40. Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, et al.: TAMI Study Group: Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990, 82:781-791.
41. Vogt A, von Essen R, Tebbe U, Feuerer W, Appel KF, Neuhaus KL, et al.: Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis for German multicenter studies. J Am Coll Cardiol 1993, 21:1391-1395.
42. Richardson SG, Allen DC, Morton P, Murtagh JG, Scott ME, O'Keefe DB, et al.: Pathological changes after streptokinase treatment in eight patients with acute myocardial infarction. Br Heart J 1989, 61:390-395.
43. Handin RI, Loscalzo J, Hemostasis, thrombosis, fibrinolysis and cardiovascular disease, edn 4. In Heart Disease. Edited by Braunwald E. Philadelphia: WB Saunders; 1991:1767-1789.
44. Eisenberg PR, Sherman LA, Jaffe AS: Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 1987, 10:527-529.
45. Gulba DC, Barthels M, Westoff-Bleck M, Jost S, Rafflenbeul W, Daniel WG, et al.: Increased thrombin levels during thrombolytic therapy in acute myocardial infaction: relevance for success of therapy. Circulation 1991, 83:937-944.
46. Fitzgerald DJ, Catella F, Roy L, Fitzgerald GA: Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infaction. Circulation 1988, 77:142-150.
47. de Bono DP, Simoons MI, Tijssen J, Arnold AE, Betriu A, Burgersdijk C, et al. for the European Cooperative Study Group: Effect of early intravenous heparin on coronary artery patency, infarct size and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperation Study Group Trial. Br Heart J 1992, 67:1222-128.
48. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM, for the Heparin-Aspirin Reperfusion Trial (HART) Investigators: A comparison between heparin and low-dose aspirin as adjuctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990, 323:1433-1437.
49. Bleich SD, Nicholas T, Schumacher RR, Cooke DH, Tate DA, Teichman SL, et al.: Effect of heparin on coronary in acute myocardial infaction. Am J Cardiol 1990, 66:1412-1417.
50. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group: ISIS-3: a randomized comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41 299 cases of suspected acute myocardial infaction. Lancet 1992, 339:753-770.
51. Tabata H, Mizunoki, Miyamto A, Etsuda H, Isojima K, Satomura K, et al.: The effect of a new thrombin inhibator (Argatrobin) in the preventation of reocclusion after reperfuction therapy in patients with acute myocardial infarction [abstract]. Circulation 1992, 86 (suppl):260. This study evaluated argatroban after thrombolytic therapy in patients with acute myocardial infarction. Argatroban infusion was associated with a significantly lower reocclusion rate at 1 month compared with herapin therapy.
52. Lidon RM, Theroux P, Lesperance J, Adelman B, Bonan R, Duval D, et al.: A pilot, early angiographic study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infaction. Circulation 1994, 89:1567-1572. This pilot study hirulog as adjunct to streptokinase therapy in acute myocardial infarction. Hirulog significantly improved the early rate of the infarct-related artery and offered a favorable clinical profile compared with herapin.
53. Neuhaus KL, Niederer W, Wagner J, Mäurer W, von Essen R, Tebbe U, et al.: HIT (Hirudin for the Improvement of Thrombolysis): results of a dose escalation study [abstract]. Circulation 1993, 88:292. This observational study evaluated the efficacy of escalating doses of hirudin as conjuctive therapy to thrombolysis in 143 patients with acute myocardial infarction. Angiographic patency was dose-dependent but bleeding complications did not increase at higher infusion rates.
54. Lincoff AM, Topol EJ: Illusion of reperfusion: does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 1993, 87:1792-1805.
55. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, et al.: A pilot trial of recombinant desulfatohirudin compared with heparin in conjuction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994, 23:993-1003. This phase II trial randomized 246 patients to either hirudin or heparin for 5 days after t-Pa for acute myocardial infarction. Patients treated with hirudin had significantly improved coronary artery patency at 18-36h, and a lower rate of reocclusion, death or recurrent myocardial infarction than patients in the heparin group.
56. Lee LV, McCabe CH, Antman EM, Koch M, Wilensky R, Stringer K, et al. for the TIMI 6 Investigators: Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the TIMI6 trial [abstract]. J Am Coll Cardiol 1994, (special issue):344A. This open-label, pilot study randomized 143 patients with acute myocardial infarction to either hirudin or heparin as adjunctive therapy to streptokinase and aspirin. There was a trend towards a lower rate of mortality and serious cardiac events in the hirudin group, compared with the heparin cohort.
57. Antman EM for the TIMI 9A Investigators: Hirudin in acute myocardial infarction: safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994, 90:1624-1630.
58. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) • II-A Investigators: Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndrome. Circulation 1994, 90:1631-1637.
59. Neuhaus K-L, van Essen R, Tebbe U, Jessel A, Heinrichs H, Mäurer W, et al.: Safety observations from the pilot of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. Circulation 1994, 90:1638-1642. The TIMI 9A [57], GUSTO IIA [58] and HIT III [59] trials were large scale, prospective phase III trials comparing hirudin with herapin as adjunctive therapy in thrombolysis. All three trials were terminated prematurely secondary to unexpectedly high rates of intracranial hemorrahage. These results suggest that hirudin, in combination with thrombolytics, has a therapeutic range narrower than previously considered.
60. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ: Abrupt vessel closure complicating coronary angioplasty: clinical angiographic and therapeutic profile. J Am Coll Cardiol 1992, 19:926-935.
61. Detre KM, Holmes DR Jr, Holubkov R, Cowley MJ, Bourassa MG, Faxon DP, et al., Coinvestigators of the National Heart, Lung, and Blood Institute's Percutaneous Transluminal Coronary Angioplasty Registry: Incidence and consequences of periprocedural occlusion. Circulation 1990, 82:739-750.
62. Topol EJ: Emerging strategies for failed percutaneous transluminal coronary angioplastry. Am J Cardiol 1989, 63:249-250.
63. Eidt JF, Allison P, Noble S, Ashton J, Golino P, McNatt J, et al.: Thrombin is an important mediator of platelet aggregation in Stenosed canine coronary arteries with endothelial injury. J Clin Invest 1989, 84:18-27.
64. McGarry TF, Gottlieb RS, Morganroth J, Zelenkofske SL, Kasparian H, Duca PR, et al.: The relationship of anticoagulation level and complication after successful percutaneous transluminal coronary angioplastry. Am Heart J 1992, 123:1445-1451.
65. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V, et al.: Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin vs. recombinant hirudin, a specific thrombin inhibitor. Circulation 1989, 79:657-665.
66. Kaiser B, Simon A, Markwardt F: Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis. Thromb Haemostasis 1990, 63:44-47.
67. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, et al.: Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993, 87:1622-1629. This is the first study using a direct thrombin inhibitor, hirulog, in place of heparin in patients undergoing coronary angioplasty. Hirulog use was associated with a dose-dependent anticoagulant effect and animal bleeding complications.
68. Van den Bos AA, Deckers JW, Heyndrickx GR, Laarman GJ, Suryapranata H, Zijlstra F, et al.: Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 1993, 88:2058-2066. In this study of hirudin infusion in patients with stable angina pectoris undergoing coronary angioplasty, hirudin was shown to be an effective inhibitor of thrombin activity with stable anticoagulant effect.
69. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, et al, for the Hirulog Angioplasty Study Investigators: Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995, 333:764-769.
70. Clarke RJ, Mayo G, Fitzgerald GA, Fitzgerald DJ: Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991, 83:1510-1518.
71. Verstraete M, Nurmohamed M, Kienast J, Siebeck M, Sillling-Engelhardt G, Büller, et al, on behalf of the European Hirudin in Thrombosis Group: Biological effects of recombinant hirudin (CGP 39 393) in human volunteers. J Am Coll Cardiol 1993, 22:1080-1088.
72. Global Use of Strategies to Open Occluded Coronary Arteries I investigators: An integrated randomized trial comparing four thrombolytic stategics for acute myocardial infarction. N Engl J Med 1993, 329:673-682.
73. Loscalzo J: Thrombin inhibitors in fibrinolysis: an Hobson's choice of alternatives. Circulation 1996, in press.
74. Sobel BE: Intracranial bleeding, fibrinolysis and anticoagulation: causal connections and clinical implications. Circulation 1994, 90:2147-2152.
75. Markwardt F: Development of hirudin as an antithrombotic agent. Semin Thromb Hemost 1989, 15:269-282.
76. Porta R, Pescador M, Mantovani M, Prino G: Quantitative comparison of recombinant hirudin's antithrombotic and anticoagulant activities with those of heparin. Thromb Res 1990, 57:639-643.
77. Gulba DC, Barthels M, Reil GH, Lichtlen PR: Thrombin/antithrombin III complex level as early predictor of reocclusion after successful thrombolysis. Lancef 1988, ii:97.
78. Eisenburg Pr, Sobel BE, Jaffe AS: Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1992, 19:1065-1069.
79. Rapold HJ, deBono D, Arnold AER, DeLock F, Collen D, Verstrete M, for the European Cooperative Study Group: Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase: correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. Circulation 1992, 85:928-934.
80. Hursting MJ, Greenberg C, Parker J, Swaim M, Cripe L, Sane D et al.: Clinical performance of a quantitative ELISA for plasma prothrombin fragment F1+2. Blood 1989, 74 (suppl1):256a.
81. Strumpf R, Eagan JT, Hardigan KT, Berg D: Assessment of new coagulation markets for intracoronary stent implantation [abstract]. Circulation 1993, 88:1-224.
82. Kiemeneij F, Laarman GJ, Swart H: Is monitoring of prothrombin factor F1+2 of additional value in guiding anticoagulation after coronary stenting? [abstract]. Circulation 1993, 88:640.
83. Scharfstein JS, George D, Burchenal JEB, Cannon CP, Becker RC, Eisenberg PR, et al., for the TIMI 5 Investigators: Hemostatic markets predict clinical events in patients with r-tPA and andjuctive antithrombotic therapy. J Am Coll Cardiol 1994, 1A:56A.
84. Granger CB, Miller JM, Bovill EG, McBane RM, Hassinger N, Gaspar D, et al.: Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995, 91:1929-1935.
85. Willerson JT, Cascells W: Thrombin inhibitors in unstable angina: rebound or continuation after argatroban withdrawal [editorial]? Am Coll Cardiol 1993, 21:1048-1051.
86. Garabedian HD, Gold HK, Hagstrom JN, Collen D, Bovill EG: Accelerated thrombin generation accompanying specific thrombin inhibition in unstable angina pectoris patients [abstract]. Circulation 1993, 88:264.
87. Zoldhelyi P, Bichler J, Owen WG, McBane RM, Harringer N, Caspar D, et al.: Measurement of thrombin-hirudin complex documents persistent thrombin formation in patients with unstable angina during anticoagulation with recombinant hirudin. [Abstract]. Circulation 1993, 88:I-319.
88. Jang I-K, Fuster V, Gold HK: Antiplatelets. Coronary Artery Dis 1992, 3:1030-1036.
89. 2 in reocclusion following coronary thrombolysis with tissue type plasminogen activator. Proc Natl Acad Sci USA 1989, 86:7585-7589.
90. Dunwiddie C, Thornberry NA, Bull HG, Sardana M, Friedman PA, Jacobs JW, et al.: Antistasin, a leech-derived inhibitor of factor Xa. J Biol Chem 1989, 264:16694-16699.
91. Vlasuk GP: Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thomb Haemostasia 1993, 70:212-216.
92. Mellot MJ, Holalhan MA, Lynch JJ, Vlasuk GP, Dunwiddie CT: Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis. Circ Res 1992, 70:1152-1160.
93. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP: Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with selective factor Xa inhibitor, tick anticoagulant peptide. Circulation 1992, 85:805-815.
94. Lynch JJ, Sitko GR, Mellott MJ, Nutt EM, Lehman ED, Friedman PA, et al.: Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition. Cardiovasc Res 1994, 28:78-85.
95. Esmon CT: The regulation of natural anticoagulation pathways. Science 1987, 235:1348-1352.
96. Rapaport SI: The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemostasis 1991, 66:6-15.
97. Benedict CR, Ryan J, Wolitzky B, Ramos R, Gerlach M, Tiburg P, et al.: Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest 1991, 88:1760-1765.
98. 410) is a potent antithrombotic agent in a rabbit model of venous thrombosis. Circulation 1992, 86 (suppl l):1-410.
99. 2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. Circulation 1992, 86:1993-1999.
100. Nicolini FA, Lee P, Rios G, Marchant K, Topol EJ: Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improved thrombolysis. Circulation 1994, 89:1802-1809.